Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
CALGARY, Aug. 28, 2017 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the following update on its corporate activities. Extension of Maturity Date of Loan The Company announced that the maturity date of the Company's CAD$68.8 million Loan (the "Loan...
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
"BETonMACE Phase 3 Trial with apabetalone to expand to include the United States " CALGARY, Alberta, July 25, 2017 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the receipt of a positive Type C written response from the Division of Metabolism ...
Resverlogix Randomizes First Patient in Taiwan/mainland China Portion of the Phase 3 BETonMACE Clinical Trial
CALGARY, Alberta, July 10, 2017 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the first patient has been randomized inTaiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular ...
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates CALGARY, Alberta, May 23, 2017 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today highlighted two additional works involving its lead drug, apab...
Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
Apabetalone expands to a second major clinical indication in kidney dialysis patients CALGARY, May 15, 2017 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the acceptance, by the Cardiovascular and Renal Products Division of the U.S. Food and D...
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
CALGARY, Alberta, Jan. 23, 2017 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced preliminary results from theNew Zealand based Phase 1 trial with severe kidney (renal) impaired patients. The data showed remarkable results in reducing inflamed protein ...
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
CALGARY, Aug. 30, 2016 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that onSunday, August 28, 2016, at the European Society of Cardiology (ESC) Congress inRome, Italy, the Company hosted a symposium entitled "A novel approach for high CV risk patien...
Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs
The commencement of this Phase 1 pharmacokinentic (PK) trial in patients with severe renal impairment is the first in a series of planned clinical trials designed with value creation in mind. CALGARY, Alberta, July 22, 2016 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:...
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
CALGARY, Alberta, Oct. 26, 2015 /PRNewswire/ -- Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced the commencement of a Phase 3 clinical trial called 'BETonMACE' with lead drug apabetalone (RVX-208) in high-risk patients with coronary artery disease (CAD) and type 2 diabetes mellitu...
Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital
CALGARY, Alberta, July 21, 2015 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix") (TSX: RVX) announced today that it has closed the previously-announced private placement with Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink") and Eastern Capital Limited ("Eastern"). Under the terms of the ...
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
CALGARY, Alberta, July 8, 2015 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has closed a license agreement and formally entered into a definitive stock purchase agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink"). The closing of the ...
Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
CALGARY, Alberta, June 22, 2015 /PRNewswire/ -- Resverlogix Corp. (TSX: RVX) today announced that following recent meetings with various European regulatory bodies, the first confirmation for our Phase 3 clinical plan has officially been received. A further regulatory and protocol design update w...
Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
CALGARY, Alberta, June 1, 2015 /PRNewswire/ -- Resverlogix Corp. (TSX: RVX) (the "Company") today announced that new data on RVX-208 was presented at the ERA-EDTA Congress inLondon, England in a poster entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key Renal ...
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
CALGARY, Alberta, April 27, 2015 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that it has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to ...
Resverlogix Receives Two Patents for RVX-208 in China
CALGARY, Alberta, April 7, 2015 /PRNewswire/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment o...
RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus
BARCELONA, Spain and CALGARY, AB, Sept. 2, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) announced today that Dr.Jan Johansson, senior vice president of medical affairs at Resverlogix delivered an oral presentation at the 2014 European Society of Cardiology (ESC) Congress inBarcelona, Spain. I...
Resverlogix Completes Dosing In ASSURE Clinical Trial
-- IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease -- TSX Exchange Symbol: RVX CALGARY, Alberta, April 18, 2013 /PRNewswire/ -- Resverlogix Corp. (TSX:RVX) today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating R...
Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders
- Transaction Designed to Enhance Shareholder Value By Unlocking Value of the Epigenetics Platform - TSX Exchange Symbol: RVX CALGARY, Alberta, April 8, 2013 /PRNewswire/ -- Resverlogix Corp. (TSX:RVX) ("Resverlogix") today announced that its Board of Directors has approved a proposal to spin-...
